Scarica l'app Stockscreener
46.58
3.20%
-1.5755
Precedente Chiudi:
$48.16
Aprire:
$48.875
Volume 24 ore:
2.23M
Relative Volume:
1.12
Capitalizzazione di mercato:
$2.94B
Reddito:
$18.09M
Utile/perdita netta:
$-208.87M
Rapporto P/E:
-13.26
EPS:
-3.5125
Flusso di cassa netto:
$-178.15M
1 W Prestazione:
+73.82%
1M Prestazione:
+87.00%
6M Prestazione:
+94.81%
1 anno Prestazione:
+208.73%
Intervallo 1D:
$46.07
$50.08
Intervallo di 1 settimana:
$26.65
$50.08
Portata 52W:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Nome
Uniqure Nv
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
46.59 | 3.04B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
452.70 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
599.52 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
880.81 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
277.03 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.25 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure Nv Borsa (QURE) Ultime notizie
QURE Maintained by RBC Capital -- Price Target Raised to $65.00 - GuruFocus
UniQure's Approval Path Looks Stronger After US FDA Feedback, RBC Capital Markets Says - marketscreener.com
uniQure (QURE) Receives Upgrade from Barclays with Increased Pri - GuruFocus
uniQure receives FDA pathway for Huntington’s disease therapy By Investing.com - Investing.com Canada
UniQure: AMT-130's FDA Path Reaffirms My Bull Case (NASDAQ:QURE) - Seeking Alpha
Barclays upgrades uniQure stock rating on Huntington’s timeline By Investing.com - Investing.com Canada
uniQure stock rating reiterated at Buy by H.C. Wainwright on FDA update - Investing.com
Leerink raises uniQure stock price target to $70 on FDA reversal - Investing.com Canada
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Uniqure NV (QURE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
RBC Raises Price Target on uniQure to $65 From $35, Keeps Outperform, Speculative Risk - marketscreener.com
uniQure shares steady after FDA momentum, Huntington’s filing on radar - TechStock²
uniQure shares leap as FDA opens door to gene therapy filing - The Pharma Letter
Uniqure NV (QURE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Uniqure NV (QURE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
QURE’s 78% FDA Shock Rally Puts uniQure Back in the Huntington’s Race - FXLeaders
Top Biotech Gainers: QURE Rallies On AMT-130 Update, LNAI On Track, FTH Eyes Q4 Data, ELTX On Watch - RTTNews
UniQure (QURE) Gains Momentum After FDA Reversal on Gene Therapy - GuruFocus
uniQure reversal puts natural-history controls back in play for rare neuro - BioCentury
[144] uniQure N.V. SEC Filing - Stock Titan
UniQure (QURE) Soars 78% on AMT-130 Progress - Insider Monkey
UniQure positioned for gains after FDA supports accelerated approval path for AMT-130 - MSN
QURE Stock Soars As FDA Backs Gene Therapy Pathway - timothysykes.com
uniQure (QURE) director exercises options, sells 10,000 shares under 10b5-1 plan - Stock Titan
Tax-driven share sale by uniQure (NASDAQ: QURE) chief legal officer - Stock Titan
UniQure (NASDAQ: QURE) notice to sell 5,295 Ordinary Shares - Stock Titan
Insider sells 11,685 UniQure shares under 10b5-1 plan (QURE) - Stock Titan
Goldman Sachs reiterates Neutral on uniQure stock after FDA meeting By Investing.com - Investing.com Nigeria
uniQure (QURE) Plans U.S. Marketing Application for Gene Therapy AMT-130 - GuruFocus
uniQure (QURE) Shares Surge Following FDA Clearance for Gene The - GuruFocus
uniQure: FDA's Latest Stance On Huntington's BLA Sends Stock Soaring (NASDAQ:QURE) - Seeking Alpha
UniQure Shares Jump After Plans Announced for FDA BLA Submission for AMT-130 in Huntington's Disease - marketscreener.com
Regenxbio stock gains after FDA's UniQure U-turn (RGNX:NASDAQ) - Seeking Alpha
Mizuho reiterates Outperform on uniQure stock, $35 target - Investing.com
UniQure surges on plans to seek US nod for gene therapy - MSN
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $50 - Moomoo
uniQure stock upgraded at Cantor on FDA decision (QURE:NASDAQ) - Seeking Alpha
uniQure stock set to rise after FDA backs BLA pathway for AMT-130 - Investing.com
uniQure (QURE) Receives Positive FDA Feedback on AMT-130 Trial - GuruFocus
QURE Stock Rockets As FDA Backs Gene Therapy Path - StocksToTrade
uniQure cleared for accelerated approval BLA submission - grafa.com
UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency - CNBC
Flexibility restored? Uniqure plans for BLA filing in Huntington’s - BioWorld News
QURE Stock Soars As FDA Boosts Gene Therapy Outlook - timothysykes.com
uniQure shares surge as FDA stance appears to reopen a near-term filing path for AMT-130 - Quiver Quantitative
FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval - Benzinga
Barclays reiterates uniQure stock rating after FDA meeting update - Investing.com
Stifel raises uniQure stock price target to $71 on FDA pathway - Investing.com
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday - Benzinga
uniQure (QURE) Sees 75% Surge in Pre-Market Trading - GuruFocus
FDA appears open to Moderna’s flu vaccine ahead of adcomm - statnews.com
Uniqure Nv Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure Nv Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Balachandran Madhavan | Director |
Jun 15 '26 |
Option Exercise |
8.49 |
10,000 |
84,900 |
53,254 |
| Balachandran Madhavan | Director |
Jun 15 '26 |
Sale |
27.85 |
10,000 |
278,500 |
43,254 |
| Potts Jeannette | Chief Legal Officer |
Jun 15 '26 |
Sale |
27.67 |
5,237 |
144,908 |
133,246 |
0.36%
2.35%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):